Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

Porta Camillo; Gore Martin E.; Rini Brian I.; Escudier Bernard; Hariharan Subramanian; Charles Lorna P.; Yang Liqiang; DeAnnuntis Liza; Motzer Robert J.

首页> 外文期刊>European urology >Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

【24h】

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

机译：舒尼替尼在转移性肾细胞癌中的长期安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to >= 6 yr.

机译：背景：接受一线舒尼替尼治疗的转移性肾细胞癌（mRCC）患者通常生存> 2年，而长期治疗有时会延长至> = 6年。

著录项

来源
《European urology》 |2016年第2期|共7页
作者
Porta Camillo; Gore Martin E.; Rini Brian I.; Escudier Bernard; Hariharan Subramanian; Charles Lorna P.; Yang Liqiang; DeAnnuntis Liza; Motzer Robert J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
Long-term safety; Renal cell carcinoma; Sunitinib; Toxicity; Treatment-related adverse events;

机译：长期安全性;肾细胞癌;舒尼替尼;毒性;治疗相关不良事件;

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma [J] . Xingming Zhang, Guangxi Sun, Jinge Zhao, Journal of Cancer . 2018,第18期

机译：转移性肾细胞癌患者的舒尼替尼给药方案从4/2切换为2/1的长期临床疗效和安全性得到改善
3. Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium [J] . Laguna M. Pilar The Journal of Urology . 2017,第3aPta1期

机译：Re：第一线瑞替尼与Pazopanib在转移性肾细胞癌中：国际转移性肾细胞癌数据库联盟的结果
4. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium [J] . Ruiz-Morales Jose Manuel, Swierkowski Marcin, Wells J. Connor, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：一线舒尼替尼与帕唑帕尼治疗转移性肾细胞癌：国际转移性肾细胞癌数据库联盟的结果
5. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
6. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
7. Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma [O] . Xingming Zhang, Guangxi Sun, Jinge Zhao, 2018

机译：转移性肾细胞癌患者的舒尼替尼给药方案从4/2转换为2/1的长期临床疗效和安全性得到改善
8. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma [O] . Camillo Porta, Martin E. Gore, Brian I. Rini, 2016

机译：Sunitinib在转移性肾细胞癌中的长期安全性

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅